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Abstract: Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased 
in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely 
empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is 
critical in preventing potentially irreversible ocular damage. However, the rise in ocular methi-
cillin-resistant Staphylococcus aureus isolates and the patterns of fluoroquinolone resistance 
for patients with other ocular bacterial infections mandate the need for new agents targeted for 
ocular use. Besifloxacin, a novel broad-spectrum fluoroquinolone, is approved for the treat-
ment of bacterial conjunctivitis. It has a uniquely balanced dual-targeting activity that inhibits 
both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance 
development. Besifloxacin is not marketed in other formulations, ensuring that its exposure is 
limited to bacterial populations in and around the eye. This specifically precludes any bacte-
rial exposure to besifloxacin resulting from systemic use, which further reduces the likelihood 
of emergence of bacterial resistance. In vitro, besifloxacin has demonstrated equivalent or 
superior activity compared with other commonly used topical antibiotics. In clinical trials, 
besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with 
bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed 
contraindications.
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Introduction
Conjunctivitis, commonly known as red eye or pink eye, is frequently the result of a 
bacterial infection but can also be caused by viruses or fungi or result from noninfectious 
origins, such as allergens, toxins, or the extended use of contact lenses.1–3 Bacterial con-
junctivitis is a contagious infection of the conjunctiva, the mucous membrane that lines 
the inner surface of the eyelids and extends over the sclera.1,4 Empiric broad-spectrum 
topical antibacterials are the usual course of therapy for bacterial conjunctivitis. Timely 
treatment of ocular infections is important, but, clinically, early recognition and treat-
ment of bacterial conjunctivitis is especially significant because of its ability to progress 
rapidly and potentially cause irreversible ocular damage, including, in rare cases, loss of 
vision.2,5 For example, development of bacterial conjunctivitis after glaucoma-filtering 
surgery has been reported to increase the patient’s risk of developing endophthalmitis.1 
Broad-spectrum empiric antibiotic therapy for bacterial conjunctivitis has been associ-
ated with substantially improved rates of clinical and microbiological remission.6
Although empiric antibiotic therapy is administered to prevent spread, speed 
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such as keratitis, this treatment approach is not without its 
own potential concerns. As the use of a particular antibiotic 
increases, the pathogens targeted by that agent tend to evolve 
and develop resistance, decreasing the treatment’s effective-
ness over time.7 The growing concern regarding antibiotic 
resistance related to the overuse of empiric antibiotic therapy 
has led to the search for newer therapies designed to address 
the development of resistance through innovative or more-
focused targeting approaches that restrict nonocular exposure 
to the antibiotic by limiting systemic availability. This paper 
will review besifloxacin, a potent new fluoroquinolone anti-
bacterial that has proven efficacy against the most common 
pathogens of bacterial conjunctivitis, has a uniquely balanced 
dual-targeting mechanism of action associated with decreased 
spontaneous resistance development, and was developed 
exclusively for topical ocular use.
Bacterial conjunctivitis
Bacterial conjunctivitis results from infections caused by a 
variety of aerobic and anaerobic bacteria. Aerobic bacteria 
tend to predominate and most commonly include Haemophilus 
influenzae, Streptococcus pneumoniae, other streptococci, 
Staphylococcus aureus, Staphylococcus epidermidis, and 
Moraxella species. Other, less common bacteria include Neis-
seria gonorrhoeae, Neisseria meningitides, Pseudomonas 
species, Proteus species, and Corynebacterium species.2
Acute bacterial conjunctivitis is demographically unbiased 
in its prevalence. It affects individuals of both genders, all 
ages, and all races. Acute or mucopurulent bacterial conjunc-
tivitis is characterized by mucopurulent or purulent discharge, 
irritation, and diffuse conjunctival hyperemia. Preauricular 
lymphadenopathy is usually not present in acute bacterial 
conjunctivitis. The acute form of the infection is caused by a 
variety of microbial pathogens; however, infections caused by 
Haemophilus species, S. pneumoniae, S. aureus, or S. epider-
midis tend to be more common.1 Bacterial conjunctivitis tends 
to be transmitted by eye-hand contact and therefore initially 
presents as a unilateral infection. However, over the course of 
a few days, the second eye may become infected.8 Because of 
its high incidence rate and broad, nonselective demographics, 
the treatment of acute bacterial conjunctivitis has been a focus 
in the development of pharmaceutical therapy.
Traditional treatment options
Ideally, acute bacterial conjunctivitis should be treated 
with an antimicrobial agent that targets the causative pathogen, 
especially in the hospital setting. However, in clinical practice, 
outpatient treatment of conjunctivitis is often empiric because 
it is initiated before causative pathogens are identified.3 
In these cases, treatment is based on the patient’s age, 
environment, and any related ocular observations. Broad-
spectrum topical antibiotics, usually eyedrops, effectively 
treat common cases of acute bacterial conjunctivitis and may 
be given as preventative treatment of a secondary infection in 
cases of viral conjunctivitis. The antibacterial agent should 
have activity against H. influenzae, S. pneumoniae, S. aureus, 
and S. epidermidis.9 Although acute bacterial conjunctivitis 
may be self-limiting, effective treatment, such as antibacte-
rial drops, can hasten clinical and microbiological recovery, 
prevent spread and transmission of the infection, reduce the 
chance of recurrence, and prevent the rare but potentially 
serious complications associated with bacterial conjuncti-
vitis. Additional preventative measures for acute bacterial 
conjunctivitis center around good hygienic practices, includ-
ing frequent hand washing, avoiding direct contact with the 
eyes, appropriate handling and cleaning of contact lenses, and 
regular replacement of eye cosmetics. It is also recommended 
that pillowcases be changed frequently and towels and hand-
kerchiefs not be shared.1,3
Fluoroquinolones
Fluoroquinolones, a class of broad-spectrum synthetic anti-
infective agents, were introduced in the late 1980s and are 
the most commonly used anti-infectives for the treatment 
of acute bacterial conjunctivitis.9 In the United States, 
6 fluoroquinolones are now marketed for ophthalmic use 
in the treatment of acute bacterial conjunctivitis. They 
include ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, 
moxifloxacin, and besifloxacin. Besifloxacin is the newest 
fluoroquinolone approved for topical ophthalmic treatment; 
however, it has unique chemical, structural, and biological 
features that differentiate it from others in its class.4
Fluoroquinolones act, with varying selectivities, through 
inhibition of the essential bacterial enzymes DNA gyrase 
and topoisomerase IV.11 In other words, they inhibit bac-
terial type II topoisomerases, leading to nonrepairable 
double-stranded DNA breaks and death of bacterial cells. 
DNA gyrase, a topoisomerase found in all types of bacte-
ria, is the primary target for gatifloxacin and moxifloxacin 
in most Gram-negative bacteria such as Escherichia coli, 
and, to a much lesser extent, in the Gram-positive species 
S. pneumoniae. On the other hand, topoisomerase IV is 
usually the primary target for most fluoroquinolones in the 
majority of Gram-positive pathogens, particularly against 
prevalent conjunctivitis pathogens such as S. aureus and S. 
epidermidis.7,12Clinical Ophthalmology 2010:4 217
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Topical fluoroquinolones approved for ocular use are all 
considered safe. However, the question of efficacy is ever 
changing based on the patterns of developing resistance. 
Newer anti-infective agents with enhanced activity and novel 
targeting mechanisms may be less prone to resistance and 
may help address this situation.
Dealing with resistance
Rates of antibiotic resistance continue to rise in both nosoco-
mial and community settings.7 Susceptibility of S. pneumoniae 
and S. aureus, two of the most common pathogens found in 
acute bacterial conjunctivitis, to many commonly employed 
antibacterial medications have demonstrated dramatic 
declines over the past decade. A recent study on S. aureus 
that summarized data submitted by more than 200 clinical 
laboratories across the United States showed that the propor-
tion of methicillin-resistance S. aureus (MRSA) isolates from 
ocular infections increased by 12.1%, from 29.5% to 41.6% 
between 2000 and 2005.13 A significant percentage (∼80%) 
of ocular MRSA isolates demonstrated in vitro resistance to 
ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and 
the aminoglycoside tobramycin.7 Patterns of fluoroquinolone 
resistance for patients with bacterial keratitis have also shown 
significant increases in resistance of S. aureus to ciprofloxacin 
(from 5.8% to 35.0%; P  0.001) and ofloxacin (from 4.7% 
to 35.0%; P  0.001) between 1993 and 1997.14
The Ocular Tracking Resistance in the United States 
Today (Ocular TRUST) study evaluated susceptibility 
patterns to ciprofloxacin, gatifloxacin, levofloxacin, moxi-
floxacin, azithromycin, tobramycin, and trimethoprim in 
prospectively collected and archived ocular isolates of 
S. aureus, S. pneumoniae, and H. influenzae.7 Ocular isolates 
of S. pneumoniae demonstrated susceptibility to all the fluo-
roquinolones tested, with the exception of 10.2% showing 
intermediate resistance to ciprofloxacin, one of the oldest fluo-
roquinolones. However, 22.4% of the isolates were resistant 
to trimethoprim, and 65.3% to tobramycin. Susceptibility of 
methicillin-susceptible S. aureus (MSSA) isolates was high 
among all the fluoroquinolones tested – ciprofloxacin (79.9%), 
levofloxacin (81.1%), gatifloxacin (81.1%), and moxifloxacin 
(81.1%) – and the aminoglycoside tobramycin (92.7%). How-
ever, susceptibility of MSSA to azithromycin was low (54.3%). 
Susceptibility of MRSA was low among all the antibacterial 
agents tested (15.2% for ciprofloxacin, levofloxacin, gatifloxa-
cin, and moxifloxacin; 6.1% for azithromycin; and 36.4% for 
tobramycin) except trimethoprim (93.9%). As a result, it has 
been suggested that the use of older, or earlier-generation, 
topical fluoroquinolones as first-line empiric therapy in ocular 
infections is supported, given that the causative pathogen has 
generally not been MRSA,7 although the above data indicate 
that this may be changing. Because treatment of bacterial 
conjunctivitis is usually empiric, the question then remains, 
which broad-spectrum topical antibacterial agent would be the 
most sensible choice for empiric outpatient therapy?
Enhanced technologies and 
improved therapeutics – besifloxacin
The continuous hurdle of emerging resistance, including 
resistance toward older fluoroquinolones, has resulted 
in a recent focus on newer fluoroquinolones that exhibit 
enhanced activity against Gram-positive bacteria, namely 
S. pneumoniae and staphylococci.12 This has led most recently 
to the development of a new fluoroquinolone that may help 
address the problem with a dual-targeted mechanism of 
action that is relatively well balanced and has shown reduced 
development of spontaneous resistance in vitro. Besifloxacin 
[(+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1- 
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolone-
3-carboxylic acid hydrochloride] is a synthetic fluoroqui-
nolone (Figure 1) indicated for topical use in patients aged 
1 year or older for the treatment of bacterial conjunctivitis 
caused by susceptible isolates of CDC coryneform group G, 
Corynebacterium pseudodiphtheriticum*, Corynebacterium 
striatum*, H. influenzae, Moraxella lacunata*, S. aureus, 
S. epidermidis, Staphylococcus hominis*, Staphylococcus 
lugdunensis*, Streptococcus mitis group, Streptococcus 
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Figure 1 Structure of besifloxacin hydrochloride. *Efficacy for these organisms was studied in fewer than 10 infections.Clinical Ophthalmology 2010:4 218
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oralis, S. pneumoniae, or Streptococcus salivarius.*15 Unlike 
other fluoroquinolones, besifloxacin is not marketed in other 
formulations for systemic use.4 This ensures that exposure 
of besifloxacin is limited to the bacterial populations in 
and around the eye. The exclusive topical ophthalmic use 
of besifloxacin precludes any bacterial exposure resulting 
from systemic use, which reduces the likelihood of resis-
tance development. Besifloxacin ophthalmic suspension 
0.6% is formulated in a mucoadhesive polymer (DuraSite®; 
InSite Vision, Inc., Alameda, CA), designed to prolong the 
drug’s residence time on the ocular surface.16 The suspension 
includes 0.01% benzalkonium chloride as a preservative. 
Benzalkonium chloride has been shown in vitro to have some 
bacteriostatic and bactericidal activities.17,18
Pharmacokinetics/pharmacodynamics
In animal studies, besifloxacin demonstrated good ocular 
penetration, with rapid absorption. A half-life of 5 to 14 hours 
was seen following a single topical dose, with an average 
Cmax of 6.43 µg/g in conjunctiva, 2.10 µg/g in cornea, and 
0.796 µg/g in aqueous humor of monkeys.19 In rabbits, 
besifloxacin demonstrated a mean residence time of more 
than 7 hours for tears, conjunctiva, and aqueous humor.20 
Conjunctival concentrations were in excess of the minimum 
inhibitory concentration required to inhibit the growth of 90% 
of organisms (MIC90) for at least 12 hours after a single dose 
for most Gram-negative and Gram-positive organisms and for 
nonresistant ophthalmic isolates. Plasma exposure following a 
single dose was long lived at very low concentrations (10 ng/
mL), demonstrating minimum systemic exposure.20
Plasma protein binding of besifloxacin was low 
and unvaried across a wide concentration range (10–
10,000 ng/mL) in rat and human plasma.20 In humans, the 
peak concentration (Cmax) of besifloxacin in tears following a 
single topical ocular dose was 610 µg/g (±540 µg/g), decreas-
ing to 1.6 µg/g at 24 hours.19 The Cmax/MIC90 ratios for besi-
floxacin in human tears following once-daily, twice-daily, and 
3-times-daily dosing regimens were 1220 or greater, and the 
area under the concentration versus time curve from time 0 to 
24 hours (AUC0–24)/MIC90 ratios were 2500 or greater against 
S. pneumoniae (0.125 µg/mL MIC90), S aureus (0.25 µg/mL 
MIC90), S. epidermidis (0.5 µg/mL MIC90), and H. influenzae 
(0.06 µg/mL MIC90). In patients with clinically diagnosed 
bacterial conjunctivitis, the Cmax of besifloxacin in plasma 
was less than 0.5 ng/mL on average, following 5 days of 
repeated 3-times-daily ocular administration. Besifloxacin 
was eliminated from human tears with an estimated half-life 
of 3.4 hours.19
Mechanism of action
Whereas older fluoroquinolones have a preference for 
either DNA gyrase or topoisomerase IV, besifloxacin has 
a more balanced targeting of both type II topoisomerases 
(Figure 2).12 The structure of besifloxacin contains the 
N-cyclopropyl group, which is associated with broad-spectrum 
activity of other fluoroquinolones, such as gatifloxacin and 
moxifloxacin. In laboratory studies investigating the target 
selectivity for besifloxacin against S. pneumoniae, S. aureus, 
and E. coli, the last as a reference pathogen, DNA gyrase 
and topoisomerase IV were both shown to be targeted by 
besifloxacin at nearly equal concentrations. Specifically, 
besifloxacin had similar activity against S. pneumoniae 
gyrase and topoisomerase IV. Besifloxacin was equally 
potent against S. pneumoniae and E. coli gyrases, which 
was not the case for ciprofloxacin or moxifloxacin. Based 
on the inhibitory activity of the antibacterial agents tested, 
besifloxacin was 5-fold more potent than was ciprofloxa-
cin and 2-fold more potent than was moxifloxacin against 
S. pneumoniae topoisomerase IV. The MICs determined for 
S. aureus mutants with defined topoisomerase mutations 
were also consistently lower for besifloxacin than for either 
ciprofloxacin or moxifloxacin. In contrast to the older fluo-
roquinolone comparators, there were no resistant mutants 
recovered for either S. aureus or S. pneumoniae at 4-fold 
MIC90s for besifloxacin.12
The molecular structure of besifloxacin also contains 
an 8-chloro and a 7-azepinyl substituent, which apparently 
further enhance potency against both type II topoisomerases 
found in bacteria.12,20,21 This dual targeting theoretically 
makes besifloxacin less prone to spontaneous resistance 
development. This is because the simultaneous occurrence 
of fluoroquinolone-resistant mutations in both DNA gyrase 
and topoisomerase IV is a highly improbable event, although 
single-step mutations in genes encoding either of the 2 type II 
topoisomerases have been frequently reported.22 Addition 
of the 8-chloro and 7-azepinyl substituents present in the 
molecular structure of besifloxacin has also been associated 
with enhanced potency and more balanced targeting of both 
essential type II bacterial topoisomerases, particularly in 
Gram-positive bacteria.10 This results in the potent activity of 
besifloxacin against Gram-positive bacteria (Table 1),21,23–25 
Gram-negative bacteria (Table 2),21,25 and anaerobic bacteria 
(Table 3).21
Spectrum of activity
Besifloxacin has demonstrated potent broad-spectrum in 
vitro activity against aerobic and anaerobic, Gram-positive Clinical Ophthalmology 2010:4 219
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Supercoiled DNA Besifloxacin Besifloxacin
DNA gyrase
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Figure 2 Dual-targeted mechanism of action for besifloxacin.
Besifloxacin binds to and inhibits 2 enzymes that are essential for maintaining bacterial DNA in the proper conformation required for DNA transcription into RNA, DNA 
replication, and bacterial cell division.
Table 1 Activities of besifloxacin and other antibiotics against Gram-positive bacteria21
Species (no. of test isolates) and test drug MICa (µg/mL)
  Range 50% 90%
Staphylococcus aureus (n = 19; CIP-Sb; 21.1% MrSAc)
  Besifloxacin 0.015–0.25 0.015 0.12
  Moxifloxacin 0.015–0.06 0.03 0.06
  Gatifloxacin 0.03–1 0.06 0.25
  Ciprofloxacin 0.12–0.5 0.25 0.5
  Levofloxacin 0.06–2 0.12 0.25
  Azithromycin 0.5 to 8 1 8
  Tobramycin 0.12–8 0.5 1
  Oxacillin 0.12 to 8 0.25 8
S. aureus (n = 11; CIP-NSd; 63.6% MrSA)
  Besifloxacin 0.03–4 0.5 4
  Moxifloxacin 0.06 to 8 4 8
  Gatifloxacin 0.12 to 8 4 8
  Ciprofloxacin 2 to 8 8 8
  Levofloxacin 0.25 to 8 8 8
  Azithromycin 0.5 to 8 8 8
  Tobramycin 0.25 to 32 1 32
  Oxacillin 0.12 to 8 8 8
Staphylococcus epidermidis (n = 9; CIP-S; 44.4% MRSEe)
  Besifloxacin 0.015–0.03 0.03 NAf
  Moxifloxacin 0.03–0.06 0.06 NA
  Gatifloxacin 0.06–0.06 0.06 NA
  Ciprofloxacin 0.12–0.12 0.12 NA
  Levofloxacin 0.12–0.12 0.12 NA
  Azithromycin 0.25 to 8 8 NA
  Tobramycin 0.008–8 0.03 NA
  Oxacillin 0.06–2 0.12 NA
S. epidermidis (n = 6; CIP-NS; 83.3% MRSE)
  Besifloxacin 0.25–4 0.25 NA
  Moxifloxacin 1 to 8 2 NA
(Continued)Clinical Ophthalmology 2010:4 220
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Table 1 (Continued)
Species (no. of test isolates) and test drug MICa (µg/mL)
  Range 50% 90%
  Gatifloxacin 1 to 8 1 NA
  Ciprofloxacin 2 to 8 8 NA
  Levofloxacin 2 to 8 8 NA
  Azithromycin 0.12 to 8 8 NA
  Tobramycin 0.06–16 2 NA
  Oxacillin 0.12–4 1 NA
Staphylococcus haemolyticus (n = 101)
  Besifloxacin 0.015–4 0.5 1
  Moxifloxacin 0.015 to 8 1 8
  Gatifloxacin 0.03 to 8 2 8
  Ciprofloxacin 0.06 to 8 8 8
  Levofloxacin 0.06 to 8 4 8
  Azithromycin 0.25 to 8 8 8
  Tobramycin 0.015 to 32 2 32
  Oxacillin 0.06 to 8 8 8
Streptococcus agalactiae (n = 100)
  Besifloxacin 0.03–0.12 0.06 0.06
  Moxifloxacin 0.06–1 0.12 0.25
  Gatifloxacin 0.12–1 0.25 0.25
  Ciprofloxacin 0.5–8 0.5 1
  Levofloxacin 0.25–4 0.5 1
  Azithromycin 0.015 to 8 0.06 8
  Tobramycin 8 to 128 32 64
  Penicillin 0.015–0.06 0.03 0.06
Streptococcus pneumoniae (n = 16; LVX-Sg)
  Besifloxacin 0.015–0.25 0.03 0.06
  Moxifloxacin 0.03–1 0.06 0.12
  Ciprofloxacin 0.12–8 0.5 2
  Levofloxacin 0.25–2 0.5 0.5
  Azithromycin 0.03 to 64 0.06 64
  Tobramycin 4–32 8 16
  Penicillin 0.06–2 0.06 0.5
S. pneumoniae (n = 85; LVX-NSh)
  Besifloxacin 0.008–1 0.5 0.5
  Moxifloxacin 0.25–8 2 4
  Ciprofloxacin 1–64 32 64
  Levofloxacin 4–32 16 16
  Azithromycin 0.03 to 64 4 64
  Tobramycin 1–32 8 16
  Penicillin 0.06–2 0.12 2
Streptococcus pyogenes (n = 101)
  Besifloxacin 0.03–0.06 0.03 0.06
  Moxifloxacin 0.06–0.5 0.12 0.25
  Gatifloxacin 0.06–0.5 0.12 0.25
  Ciprofloxacin 0.12–2 0.5 0.5
  Levofloxacin 0.25–2 0.5 0.5
  Azithromycin 0.03 to 8 0.06 8
  Tobramycin 4–64 16 16
  Penicillin 0.015–0.06 0.015 0.015
aMinimum inhibitory concentration; bCiprofloxacin susceptible; cMethicillin-resistant Staphylococcus aureus; dCiprofloxacin nonsusceptible; eMethicillin-resistant Staphylococcus 
epidermidis; fNot available; gLevofloxacin susceptible; hLevofloxacin nonsusceptible.Clinical Ophthalmology 2010:4 221
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Table 2 Activities of besifloxacin and other antibiotics against Gram-negative bacteria21
Species (no. of test isolates) and test drug MICa (µg/mL)
  Range 50% 90%
Haemophilus influenzae (n = 15; CIP-Sb)
  Besifloxacin 0.008–0.25 0.015 0.03
  Moxifloxacin 0.015–0.05 0.015 0.06
  Ciprofloxacin 0.008–1 0.008 0.015
  Levofloxacin 0.008–1 0.015 0.015
  Azithromycin 0.12–2 2 2
  Tobramycin 1–16 2 8
  Penicillin 0.25 to 4 0.5 4
H. influenzae (n = 11; CIP-NSc)
  Besifloxacin 0.015–2 2 2
  Moxifloxacin 1–16 8 16
  Ciprofloxacin 2–64 16 64
  Levofloxacin 1–32 8 16
  Azithromycin 0.5–8 1 8
  Tobramycin 1–16 4 8
  Penicillin 0.5 to 4 1 2
Moraxella catarrhalis (n = 101)
  Besifloxacin 0.015–0.12 0.03 0.03
  Moxifloxacin 0.015–0.12 0.03 0.03
  Gatifloxacin 0.008–0.25 0.015 0.015
  Ciprofloxacin 0.008–0.25 0.015 0.015
  Levofloxacin 0.015–0.5 0.015 0.03
  Azithromycin 0.015–0.06 0.03 0.03
  Tobramycin 0.03–0.5 0.25 0.25
  Penicillin 0.25 to 8 4 8
Neisseria meningitides (n = 20)
  Besifloxacin 0.004–0.03 0.008 0.015
  Moxifloxacin 0.004–0.015 0.008 0.008
  Ciprofloxacin 0.002–0.015 0.004 0.004
  Levofloxacin 0.004–0.03 0.008 0.015
  Azithromycin 0.03–0.12 0.06 0.06
  Penicillin 0.06–0.25 0.06 0.12
Proteus mirabilis (n = 50)
  Besifloxacin 0.06–32 0.25 16
  Moxifloxacin 0.06–128 0.25 16
  Ciprofloxacin 0.015 to 128 0.03 32
  Levofloxacin 0.015–32 0.03 8
  imipenem 0.06–4 1 2
  Tobramycin 0.25–32 1 4
  Ceftazidime 0.03–16 0.03 0.06
Proteus vulgaris (n = 50)
  Besifloxacin 0.06–1 0.12 0.25
  Moxifloxacin 0.06–2 0.25 0.5
  Ciprofloxacin 0.008–0.12 0.015 0.03
  Levofloxacin 0.015–0.25 0.03 0.06
  imipenem 0.25–4 1 4
  Tobramycin 0.25–64 1 2
  Ceftazidime 0.03–2 0.06 0.12
Pseudomonas aeruginosa (n = 105; CIP-S)
  Besifloxacin 0.5–8 1 4
  Moxifloxacin 0.5–16 2 4
  Ciprofloxacin 0.03–1 0.12 0.5
  Levofloxacin 0.06–4 0.5 1
(Continued)Clinical Ophthalmology 2010:4 222
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and Gram-negative bacteria, including H. influenzae, 
S. pneumoniae, S. aureus, and S. epidermidis, relative 
to that of other fluoroquinolones.12,21 Besifloxacin, along 
with nadifloxacin, ofloxacin, and sparfloxacin, was tested 
in vitro against isolates of Gram-negative, Gram-positive, 
and anaerobic bacteria.21 No substantial differences in 
MIC values were observed across the 4 fluoroquinolones 
for the Gram-negative organisms. For Gram-positive 
bacteria, which included a variety of Staphylococcus 
species (including MRSA) and Streptococcus species, 
besifloxacin demonstrated notably more potent inhibi-
tion than did ofloxacin. Besifloxacin also demonstrated 
4.5-fold more potent inhibition than nadifloxacin and 
4.4-fold more potent inhibition than sparfloxacin against 
Gram-positive bacteria and similar activity to the 2 agents 
against MRSA. Finally, besifloxacin was significantly more 
potent against anaerobic bacteria than was either ofloxacin 
or nadifloxacin.20
In a recent laboratory analysis evaluating the broad-
spectrum activity of besifloxacin, 2690 clinical isolates, 
including 34 aerobic and 6 anaerobic bacterial species, were 
tested for susceptibility to besifloxacin and a wide range of 
other commonly used antibacterial agents, including other 
fluoroquinolones.21 The in vitro activity of besifloxacin 
against isolates of Gram-negative, Gram-positive, and 
anaerobic bacteria was generally equivalent or superior to 
that of topical antibacterial agents commonly used to treat 
ocular infections. Agents tested included ciprofloxacin, 
moxifloxacin, levofloxacin, gatifloxacin, azithromycin, and 
tobramycin, among others. In particular, besifloxacin was 
Table 2 (Continued )
Species (no. of test isolates) and test drug MICa (µg/mL)
  Range 50% 90%
  imipenem 0.5 to 8 2 2
  Tobramycin 0.25 to 64 0.5 1
  Ceftazidime 0.5 to 16 2 8
P. aeruginosa (n = 96; CIP-NS)
  Besifloxacin 2–128 16 64
  Moxifloxacin 2 to 128 64 128
  Ciprofloxacin 2 to 128 16 64
  Levofloxacin 2 to 128 16 64
  imipenem 0.25 to 8 8 8
  Tobramycin 0.25 to 64 1 64
  Ceftazidime 0.25 to 16 4 16
aMinimum inhibitory concentration; bCiprofloxacin susceptible; cCiprofloxacin nonsusceptible.
Table 3 Activities of besifloxacin and other antibiotics against 
anaerobic bacteria21
Species (no of test isolates)  
and test drug
MICa (µg/mL)
  Range 50% 90%
Clostridium perfringens (n = 21)
  Besifloxacin 0.12–0.25 0.25 0.25
  Moxifloxacin 0.25–0.5 0.5 0.5
  Gatifloxacin 0.5–1 1 1
  Clindamycin 0.06–4 2 4
  Metronidazole 1–4 2 4
Fusobacterium species (n = 21)
  Besifloxacin 0.12–8 0.25 1
  Moxifloxacin 0.25 to 16 1 2
  Gatifloxacin 0.5 to 16 1 4
  Clindamycin 0.06–8 0.06 2
  Metronidazole 0.12–2 0.25 1
Peptostreptococcus species (n = 52)
  Besifloxacin 0.06–2 0.25 0.5
  Moxifloxacin 0.25–4 0.25 0.5
  Ciprofloxacin 0.5 to 8 2 4
  Clindamycin 0.06 to 8 0.25 8
  Metronidazole 0.03 to 16 0.5 1
Propionibacterium acnes (n = 21)
  Besifloxacin 0.12–0.25 0.25 0.25
  Moxifloxacin 0.25–0.25 0.25 0.25
  Gatifloxacin 0.25–0.5 0.25 0.5
  Clindamycin 0.03–2 0.06 0.12
  Metronidazole 16 to 16 16 16
aMinimum inhibitory concentration.Clinical Ophthalmology 2010:4 223
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was noninferior to moxifloxacin for clinical resolution 
on day 5 (58.3% vs 59.4%, respectively; 95% confidence 
interval [CI], -9.48 to 7.29) and on day 8 (84.5% vs 84.0%, 
respectively; 95% CI, -5.67 to 6.75).25 Besifloxacin was 
also noninferior to moxifloxacin for microbial eradication 
on day 5 (93.3% vs 91.1%, respectively; 95% CI, -2.44 
to 6.74) and on day 8 (87.3% vs 84.7%, respectively; 95% 
CI, -3.32 to 8.53).
Safety and tolerability
Besifloxacin is considered safe and is well tolerated with 
no observed contraindications. In clinical trials, the most 
common adverse event reported was conjunctival redness, 
occurring in approximately 2% of patients.15 Tables 426 
and 527 highlight the most common treatment-emergent 
ocular adverse events observed across the above-mentioned 
3 clinical studies for study eyes and for all treated eyes 
(patients with bilateral conjunctivitis had both the study eye 
and fellow eye treated), respectively.
Data drawn from phase 1 studies demonstrated that topi-
cal ocular administration of besifloxacin resulted in negligible 
systemic exposure, with no changes in corneal endothelial 
cell density.27 In a vehicle-controlled trial of 957 adult patients 
with bacterial conjunctivitis, a greater percentage of eyes 
treated with vehicle experienced adverse effects than did 
those treated with besifloxacin (13.9% vs 9.2%, respectively; 
P = 0.0047).23 In another randomized, vehicle-controlled 
trial of 118 patients, there was no significant difference of 
cumulative adverse events between placebo and besifloxacin 
groups.24 Finally, in a randomized trial of 1161 patients 
treated with either besifloxacin or moxifloxacin, both drugs 
were well tolerated.25 Patients treated with moxifloxacin 
markedly more potent against non–ciprofloxacin-susceptible 
S. aureus than were all other ophthalmic fluoroquinolones 
(MIC90 4 µg/mL vs 8 µg/mL, respectively). Besifloxacin 
was also far more potent than were other fluoroquinolones 
against staphylococcal isolates that were both methicillin- 
and fluoroquinolone-resistant. In short, the activity of besi-
floxacin against staphylococci was substantially improved 
compared with the activities observed for azithromycin, 
tobramycin, and all other fluoroquinolone comparators. Besi-
floxacin activity was generally comparable to that of other 
fluoroquinolones against ciprofloxacin-susceptible isolates 
of Gram-negative aerobes. Finally, besifloxacin and moxi-
floxacin were the most active of the agents tested against 
anaerobic bacteria. Overall, besifloxacin demonstrated 
potent activity against Gram-positive bacteria that were 
resistant to other fluoroquinolones. See Tables 1 through 3 
for detailed results.21
Clinical efficacy
In clinical trials, besifloxacin has demonstrated efficacy 
and safety in the treatment of patients with bacterial 
conjunctivitis. In a phase 3 randomized, multicenter, 
double-masked, vehicle-controlled trial of 390 patients 
with culture-confirmed bacterial conjunctivitis, besifloxacin 
demonstrated significant efficacy in clinical resolution and 
microbial eradication compared with vehicle.23 At day 5, 
clinical resolution was 45.2% for besifloxacin, compared 
with 33.0% for vehicle (P = 0.0084). Microbial eradica-
tion was 91.5% vs 59.7%, respectively (P  0.0001). On 
day 8, clinical resolution was 84.4% vs 69.1%, respectively 
(P = 0.0011), and microbial eradication was 88.4% vs 71.7%, 
respectively (P  0.0001).
In another multicenter, prospective, randomized, vehicle-
controlled trial (N = 118 culture-confirmed cases of acute 
bacterial conjunctivitis), patients receiving besifloxacin 
(n = 60) had a significantly higher rate of clinical resolution 
of baseline symptoms at day 8 than did patients receiving 
vehicle (n = 58) (73.3% vs 43.1%, respectively; P  0.001).24 
Besifloxacin also had a significantly higher rate of bacterial 
eradication than did vehicle at this visit (88.3% vs 60.3%, 
respectively; P  0.001). This trial demonstrated that besi-
floxacin (ophthalmic suspension 0.6%) 3 times daily for 
5 days is effective in attaining clinical resolution of symptoms 
associated with bacterial conjunctivitis and in eradicating the 
bacteria that cause the disease.
Finally, in a multicenter, randomized, double-masked, 
active-controlled noninferiority study of 1161 patients (533 
with culture-confirmed bacterial conjunctivitis), besifloxacin 
Table 4 Pooled analysis: treatment-emergent ocular adverse events 
(Aes) in 1.0% of all treated study eyes in any treatment group26
Patients, n (%)
   Besifloxacin 
(n = 1192)
Vehicle 
(n = 616)
Moxifloxacin 
(n = 579)
P valuea 
Total no. of AEs 191 146 81
Patients with 
1 Ae
139 (11.7) 101 
(16.4)
54 (9.3) 0.0055
vision blurred 25 (2.1) 24 (3.9) 3 (0.5) 0.0318
eye irritation 17 (1.4) 18 (2.9) 8 (1.4) 0.0457
eye pain 22 (1.8) 11 (1.8) 7 (1.2) 0.9999
Conjunctivitis 14 (1.2) 15 (2.4) 5 (0.9) 0.0492
eye pruritus 13 (1.1) 10 (1.6) 2 (0.3) 0.3777
Conjunctivitis, 
bacterial
7 (0.6)  9 (1.5)  2 (0.3)  0.0678 
aP values were based on Fisher’s exact test comparing besifloxacin with vehicle.Clinical Ophthalmology 2010:4 224
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did have a significantly higher incidence of eye irritation 
(1.4% vs 0.3% for besifloxacin; P = 0.0201); however, all 
other adverse events occurred with similar frequency between 
both agents.
A subanalysis of adverse events among patients less 
than 6 years of age from the above studies demonstrated the 
safety and efficacy of besifloxacin ophthalmic suspension 
0.6% in this population.28 The most common adverse events 
reported in patients less than 6 years of age were conjunc-
tivitis (2.1%, 7/331), bacterial conjunctivitis (1.8%, 6/331), 
conjunctival hemorrhage (1.2%, 4/331), viral conjunctivitis 
(1.2%, 4/331), and eye pain (1.2%, 4/331). As an adverse 
event, conjunctivitis was reported less frequently in patients 
receiving besifloxacin than in patients receiving vehicle.
Finally, in a rabbit wound-healing model using dexa-
methasone as a positive control, planimetry measurements 
showed that besifloxacin did not impede corneal reepitheli-
alization compared with saline at 72 hours.29
Dosing
The recommended dosage of besifloxacin is 1 drop of the 
besifloxacin ophthalmic suspension 0.6% in the affected 
eye 3 times a day, at intervals of 4 to 12 hours, for a total 
of 7 days.15 The dosing frequency for besifloxacin is 
similar to that for moxifloxacin, whereas other ophthalmic 
fluoroquinolones are administered more frequently,4 possibly 
leading to compliance issues, an important consideration in 
the fight against emerging microbial resistance. Compliance 
has been shown to be inversely related to frequency and 
complexity of dosing.30 The convenience of besifloxacin is 
further enhanced by the recommended intervals between 
doses, which can range from 4 to 12 hours, adding a degree 
of flexibility.15
Besifloxacin is supplied as an ophthalmic suspension with 
benzalkonium chloride as a preservative, and the closed bottle 
should be inverted and shaken once prior to use.
Conclusions
Besifloxacin is a novel synthetic, broad-spectrum fluoroqui-
nolone recently approved for the treatment of bacterial con-
junctivitis. Clinical trials have demonstrated superior efficacy 
of besifloxacin to that of vehicle and clinical equivalence 
(noninferiority) to that of moxifloxacin. In vitro, besifloxacin 
has demonstrated potent activity often superior to that of other 
commonly used topical anti-infectives. Besifloxacin has a 
uniquely balanced dual-targeting activity that inhibits both 
DNA gyrase and topoisomerase IV and potentially hinders 
the rise of resistance. Unlike other fluoroquinolones, besi-
floxacin has highly selective usage. It is formulated only for 
ocular use and is neither marketed nor in development in for-
mulations for systemic administration. The reduced exposure 
of besifloxacin to bacterial populations will presumably limit 
the likelihood of the emergence of bacterial resistance result-
ing from any nonocular exposure to the drug, although cross-
resistance from other fluoroquinolones has been observed. 
Taking into account the changing susceptibility profiles of 
the major causative pathogens, the first-line use of a potent 
new ophthalmic fluoroquinolone with a lower potential for 
resistance development may result in an improved resistance 
development profile relative to that of the other ophthalmic 
fluoroquinolones, all of which have also been used for more 
than 10 years in a broad variety of nonophthalmic health 
care – and community-associated infection settings.
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Table 5 Pooled analysis: treatment-emergent ocular adverse events 
(Aes) in 1% of all treated eyesa in any treatment group (safety 
population)27
  
 
Besifloxacin 
(n = 1810) 
n (%)
Vehicle 
(n = 961) 
n (%)
Vigamox 
(n = 855) 
n (%)
P valueb 
 
Total no of  
ocular Aes
327 258 153
eyes with  
1 Ae
249 (13.8) 190 (19.8) 120 (14.0) 0.0001
Conjunctivitis 47 (2.6) 41 (4.3) 33 (3.9) 0.0223
vision blurred 38 (2.1) 39 (4.1) 4 (0.5) 0.0035
Conjunctivitis, 
bacterial
32 (1.8) 27 (2.8) 22 (2.6) 0.0736
eye irritation 26 (1.4) 27 (2.8) 12 (1.4) 0.0187
eye pain 28 (1.5) 17 (1.8) 9 (1.1) 0.6396
eye pruritus 18 (1.0) 18 (1.9) 3 (0.4) 0.0761
aTreated eyes, including study and fellow eyes; bP values for besifloxacin compared 
with vehicle (Fisher’s exact test).Clinical Ophthalmology 2010:4
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